NCT05844033View on ClinicalTrials.gov

Biomarker for Infection Risk in CLL and MM

Active, not recruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

March 31, 2027

Conditions

Multiple MyelomaChronic Lymphocytic Leukemia

Interventions

OTHER

Screening

Blood tests

Trial Locations (1)

02215

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

Massachusetts General Hospital

OTHER